European Journal of Molecular & Clinical Medicine

Abstract

The frequency of cirrhosis is about 20–40 cases per 100,000 populations, and this indicator is steadily increasing. At present, it is one of the six main causes of death at the age of 35–60 years in economically developed countries. Foreign and domestic scientists are working on the development and synthesis of new drugs of chemical and natural origin for the treatment and prevention of liver diseases of various origins, in particular liver cirrhosis. Many studies have shown an important pathogenic role in the occurrence and progression of some liver diseases with changes in the intestinal microbiota. Therefore, antibiotics, prebiotics and probiotics are an effective treatment for liver diseases, which can correct the intestinal microbiota.